NanJing Pharmaceutical Company Limited (SHA:600713)
China
· Delayed Price · Currency is CNY 5.29
+0.07 (1.34%)
Jul 16, 2025, 2:45 PM CST
SHA:600713 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 53,568 | 53,473 | 50,074 | 44,964 | 39,700 | Upgrade
|
Other Revenue | 128.05 | 116.29 | 147.48 | 159.08 | 117.15 | Upgrade
|
| 53,696 | 53,590 | 50,222 | 45,123 | 39,817 | Upgrade
| |
Revenue Growth (YoY) | 0.20% | 6.71% | 11.30% | 13.33% | 7.16% | Upgrade
|
Cost of Revenue | 50,341 | 50,283 | 46,969 | 42,190 | 37,297 | Upgrade
|
Gross Profit | 3,355 | 3,307 | 3,252 | 2,934 | 2,520 | Upgrade
|
Selling, General & Admin | 1,666 | 1,691 | 1,645 | 1,509 | 1,358 | Upgrade
|
Research & Development | 30.64 | 36.19 | 27.43 | 20.96 | 16 | Upgrade
|
Other Operating Expenses | 94.31 | 96.35 | 116.55 | 91.37 | 73.75 | Upgrade
|
Operating Expenses | 1,818 | 1,807 | 1,864 | 1,633 | 1,493 | Upgrade
|
Operating Income | 1,537 | 1,500 | 1,389 | 1,301 | 1,027 | Upgrade
|
Interest Expense | -494.18 | -522.23 | -332.9 | -439 | -363.83 | Upgrade
|
Interest & Investment Income | 17.62 | 18.72 | 11.41 | 13.17 | 12.47 | Upgrade
|
Other Non Operating Income (Expenses) | -50.1 | -19.42 | -136.95 | -17.44 | -8.08 | Upgrade
|
EBT Excluding Unusual Items | 1,011 | 977.09 | 930.24 | 857.44 | 667.98 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | -48.64 | -87.74 | -92.92 | Upgrade
|
Gain (Loss) on Sale of Assets | 3.77 | 1.75 | 23.79 | 60.54 | 66.12 | Upgrade
|
Other Unusual Items | -10.94 | -0.77 | 0.63 | 8.63 | 36.62 | Upgrade
|
Pretax Income | 1,003 | 978.07 | 906.01 | 838.87 | 677.8 | Upgrade
|
Income Tax Expense | 260.28 | 265.26 | 190.09 | 228.31 | 207.76 | Upgrade
|
Earnings From Continuing Operations | 743.12 | 712.81 | 715.92 | 610.55 | 470.04 | Upgrade
|
Minority Interest in Earnings | -172.49 | -134.98 | -120.25 | -105.37 | -93.62 | Upgrade
|
Net Income | 570.63 | 577.83 | 595.67 | 505.18 | 376.41 | Upgrade
|
Net Income to Common | 570.63 | 577.83 | 595.67 | 505.18 | 376.41 | Upgrade
|
Net Income Growth | -1.25% | -3.00% | 17.91% | 34.21% | 8.50% | Upgrade
|
Shares Outstanding (Basic) | 1,303 | 1,298 | 1,254 | 1,042 | 1,043 | Upgrade
|
Shares Outstanding (Diluted) | 1,303 | 1,298 | 1,254 | 1,042 | 1,043 | Upgrade
|
Shares Change (YoY) | 0.33% | 3.54% | 20.39% | -0.10% | 0.09% | Upgrade
|
EPS (Basic) | 0.44 | 0.45 | 0.47 | 0.48 | 0.36 | Upgrade
|
EPS (Diluted) | 0.44 | 0.45 | 0.47 | 0.48 | 0.36 | Upgrade
|
EPS Growth | -1.57% | -6.32% | -2.06% | 34.35% | 8.41% | Upgrade
|
Free Cash Flow | 1,591 | 1,748 | -837.59 | 388.79 | -1,399 | Upgrade
|
Free Cash Flow Per Share | 1.22 | 1.35 | -0.67 | 0.37 | -1.34 | Upgrade
|
Dividend Per Share | 0.170 | 0.160 | 0.140 | 0.120 | 0.110 | Upgrade
|
Dividend Growth | 6.25% | 14.29% | 16.67% | 9.09% | 10.00% | Upgrade
|
Gross Margin | 6.25% | 6.17% | 6.48% | 6.50% | 6.33% | Upgrade
|
Operating Margin | 2.86% | 2.80% | 2.77% | 2.88% | 2.58% | Upgrade
|
Profit Margin | 1.06% | 1.08% | 1.19% | 1.12% | 0.95% | Upgrade
|
Free Cash Flow Margin | 2.96% | 3.26% | -1.67% | 0.86% | -3.52% | Upgrade
|
EBITDA | 1,674 | 1,654 | 1,543 | 1,448 | 1,163 | Upgrade
|
EBITDA Margin | 3.12% | 3.09% | 3.07% | 3.21% | 2.92% | Upgrade
|
D&A For EBITDA | 136.53 | 153.76 | 153.84 | 147.27 | 135.81 | Upgrade
|
EBIT | 1,537 | 1,500 | 1,389 | 1,301 | 1,027 | Upgrade
|
EBIT Margin | 2.86% | 2.80% | 2.77% | 2.88% | 2.58% | Upgrade
|
Effective Tax Rate | 25.94% | 27.12% | 20.98% | 27.22% | 30.65% | Upgrade
|
Revenue as Reported | 53,696 | 53,590 | 50,222 | 45,123 | 39,817 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.